Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
15.4M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
15.4M
-
Shares change
-
-1.07M
-
Total reported value, excl. options
-
$230M
-
Value change
-
-$13.6M
-
Put/Call ratio
-
0.29
-
Number of buys
-
35
-
Number of sells
-
-40
-
Price
-
$14.95
Significant Holders of Neurogene Inc. - Common Stock (NGNE) as of Q2 2025
99 filings reported holding NGNE - Neurogene Inc. - Common Stock as of Q2 2025.
Neurogene Inc. - Common Stock (NGNE) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.4M shares
of 15.4M outstanding shares and own 99.98% of the company stock.
Largest 10 shareholders include SAMSARA BIOCAPITAL, LLC (1.72M shares), RTW INVESTMENTS, LP (1.36M shares), Casdin Capital, LLC (1.3M shares), Redmile Group, LLC (1.28M shares), EcoR1 Capital, LLC (1.27M shares), BAKER BROS. ADVISORS LP (992K shares), BlackRock, Inc. (978K shares), TORONTO DOMINION BANK (681K shares), VANGUARD GROUP INC (610K shares), and ArrowMark Colorado Holdings LLC (585K shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.